Results 31 to 40 of about 1,680 (126)

Emicizumab: the hemophilia A game changer

Haematologica, 2023
In hemophilia, the unmet needs regarding adherence to prophylaxis and lack of effective longterm prophylaxis regimens, especially in patients with inhibitors, led to the production of emicizumab, the first non-factor medicine for subcutaneous administration in patients with severe and moderate hemophilia A with or without factor VIII inhibitors.
Pedro E. Alcedo Andrade, Pier Mannuccio Mannucci, Craig M. Kessler   +2 more
openaire   +3 more sources

Predicting Recovery After Joint Bleeding in Persons With Bleeding Disorders

Haemophilia, EarlyView.
ABSTRACT Introduction Joint bleeds are burdensome and recovery differs from bleed to bleed. Identifying predictors of recovery could enable personalized treatment and monitoring; aiming to prevent long‐term joint deterioration, and facilitate faster return to activities. Aim To identify predictors of time to recovery after joint bleeding in people with
Gijs Aertssen, Lize F. D. van Vulpen, Wouter Foppen, Flora H. P. van Leeuwen, Merel A. Timmer   +4 more
wiley   +1 more source

Factors Influencing Sport‐Induced Bleeding in Patients With Haemophilia Without Inhibitors: A Single Centre Retrospective Study of People Born in the 2000s

Haemophilia, EarlyView.
ABSTRACT Introduction Recent advances in prophylaxis with clotting factor concentrates have enabled people with haemophilia (PwH) to participate in high‐intensity exercises; however, this does not preclude them from sports‐induced bleeding (SIB). Aim To investigate factors influencing the recent occurrence of SIB among PwH.
Rie Shirayama, Takuma Ito, Tetsuji Sato, Takayuki Hoshina   +3 more
wiley   +1 more source

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China

Frontiers in Pediatrics, 2022
BackgroundAs a new non-factor therapy for hemophilia A (HA), real-world study of emicizumab is still scarce. This study aimed to investigate the real-world use of emicizumab in Chinese boys with HA.MethodsPatients with moderate or severe HA were enrolled
Guoqing Liu, Kun Huang, Gang Li, Yingzi Zhen, Zhengping Li, Zhenping Chen, Runhui Wu   +6 more
doaj   +1 more source

Emicizumab in tolerized patients with hemophilia A with inhibitors: A single‐institution pediatric cohort assessing inhibitor status

Research and Practice in Thrombosis and Haemostasis, 2021
Background The majority of patients with hemophilia A with inhibitors who undergo immune tolerance induction (ITI) achieve successful tolerance and transition to factor VIII (FVIII) prophylaxis. A portion of these patients have switched to emicizumab for
Glaivy Batsuli, Amanda Greene, Shannon L. Meeks, Robert F. Sidonio Jr   +3 more
doaj   +1 more source

Modeling Benefits, Costs, and Affordability of a Novel Gene Therapy in Hemophilia A

HemaSphere, 2022
The objective was to undertake an early cost-effectiveness assessment of valoctocogene roxaparvovec (valrox; Roctavian) compared to factor (F)VIII prophylaxis or emicizumab (Hemlibra; Roche HQ, Bazel, Switzerland) in patients with severe Hemophilia A (HA)
Renske M.T. ten Ham, Sikon M. Walker, Marta O. Soares, Geert W.J. Frederix, Frank W.G. Leebeek, Kathelijn Fischer, Michiel Coppens, Stephen J. Palmer   +7 more
doaj   +1 more source

Thrombin Generation in Pediatric Haemophilia A Patients on Extended Half‐Life FVIII versus Non‐FVIII Therapies

Haemophilia, EarlyView.
ABSTRACT Introduction The therapeutic landscape for patients with haemophilia A (PwHA) is rapidly evolving with the introduction of extended half‐life FVIII (EHL‐FVIII) and non‐FVIII therapies that mimic FVIII, such as emicizumab (EMI). Monitoring non‐factor therapies in the laboratory poses challenges; however, the thrombin generation assay (TGA) can ...
Jessica Garcia, Sean G. Yates, Ravi Sarode, Guy Young, Ayesha Zia   +4 more
wiley   +1 more source

Laboratory Assessment of Emicizumab Levels in Hemophilia A: Influence of Assay Selection on Reported Results

Clinical and Applied Thrombosis/Hemostasis
Background Emicizumab has emerged as a promising therapy for hemophilia A (HA), employing a bypassing mechanism to restore hemostasis. However, since the traditional factor assays cannot be used for measuring the effect of emicizumab, treatment ...
Charlotte Gran MD, PhD, Tony Frisk MD, PhD, Margareta Homström MD, PhD, Maria Magnusson MD, PhD, Susanna Ranta MD, PhD, Anna Sjöström MD, PhD, Marjan Shafaati Lambert, Nida Mahmoud Hourani Soutari BSc, Jovan P. Antovic MD, PhD, Roza Chaireti MD, PhD   +9 more
doaj   +1 more source

Cuantificación plasmática de emicizumab

Revista Hematología, 2022
El emicizumab (Hemlibra®, Roche) es un anticuerpo monoclonal IgG4 bi-específico, recombinante y humanizado, con afinidad por el FIXa y el FX, mimetizando la función del FVIIIa. Su administración por vía subcutánea es eficaz y segura en la prevención de hemorragias en pacientes con hemofilia A severa con o sin inhibidor.
Emanuel Sueldo, E Annetta, J Frontroth, M Hepner   +3 more
openaire   +1 more source

Activated protein C resistance in the copresence of emicizumab and activated prothrombin complex concentrates

Research and Practice in Thrombosis and Haemostasis
Background: Venous thromboembolic events have been reported in persons with hemophilia A who received emicizumab and activated prothrombin complex concentrate (APCC) concomitantly, but the relevant mechanism(s) remains unclear.
Yuto Nakajima, Mitsumasa Osuna, Kuniyoshi Mizumachi, Naruto Shimonishi, Shoko Furukawa, Kenichi Ogiwara, Keiji Nogami   +6 more
doaj   +1 more source